Exhibit 99.1
News Release
MyoKardia Reports Second Quarter 2020 Financial Results
Brisbane, Calif., August 4, 2020 -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the second quarter ended June 30, 2020.
“The second quarter of 2020 was one of incredible progress across our R&D pipeline, including the exciting new data from our danicamtiv program highlighting its unique ability to directly activate both the left atrium and the left ventricle, and capped off by the positive results from our pivotal Phase 3 EXPLORER trial. These data, together with a successful financing, position us well in the pursuit of our mission to change the world for the tens of millions of people with serious cardiovascular disease,” said Tassos Gianakakos, MyoKardia’s Chief Executive Officer. “We are highly focused on the U.S. regulatory approval and successful launch of mavacamten and continue to develop evidence supporting its potential as a backbone therapy for people with HCM and possibly beyond. Beyond mavacamten and danicamtiv, the application of our R&D platform continues to be fruitful and is generating proprietary scientific insights that could lead to several important new therapies.”
Clinical Program Highlights
Mavacamten for Hypertrophic Cardiomyopathy
| • | Positive Phase 3 Topline Data from EXPLORER-HCM: MyoKardia announced positive topline data from its Phase 3 pivotal EXPLORER-HCM clinical trial of mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Mavacamten demonstrated a robust treatment effect: the primary and all secondary endpoints were met with statistical significance (p≤0.0006). Mavacamten was well tolerated, and meaningful improvements in symptoms, functional status and quality of life, as well as reduction or elimination in obstruction of the left ventricle, were observed among patients on treatment versus placebo. |
| • | EXPLORER Data Accepted for Late-Breaker Presentation at ESC 2020: The Phase 3 data from the EXPLORER-HCM clinical trial have been accepted as a late-breaker presentation at the upcoming virtual European Society of Cardiology (ESC) meeting. Dr. Iacopo Olivotto, from the Careggi University Hospital, Florence, Italy, will present the data on Saturday, August 29, 2020 at 6:30 CET. |
| • | Breakthrough Therapy Designation Granted by FDA: MyoKardia announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to mavacamten for the treatment of symptomatic, obstructive HCM. Breakthrough Therapy Designation is intended to expedite the development and review of a drug candidate that is planned for use to treat a serious or life-threatening disease or condition when clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. MyoKardia plans to submit a New Drug Application to the FDA in the first quarter of 2021. |
| • | Initiated VALOR-HCM Phase 3 Clinical Trial: The Phase 3 VALOR-HCM trial is a randomized, double-blind, placebo-controlled, multicenter study designed to provide direct clinical evidence of mavacamten’s ability to improve outcomes for individuals with HCM by reducing the need for invasive septal reduction therapy (SRT) procedures. VALOR-HCM is being conducted in partnership with Cleveland Clinic C5Research, an academic research organization, with participation from approximately 15 HCM specialty centers with well-recognized expertise in SRT procedures in the U.S. |
Driven by the Heart
333 Allerton Avenue, South San Francisco, CA 94080 / +1 650 351 4705 / myokardia.com
Danicamtiv for Dilated Cardiomyopathy
| • | Presented and Published Encouraging Danicamtiv Clinical and Non-clinical Data: In a Phase 2a clinical trial, danicamtiv was generally well-tolerated in patients with stable chronic heart failure and was associated with clinically meaningful improvements in left ventricular (LV) contractility, including statistically significant increases in LV stroke volume, without impairing the heart’s ability to relax and fill. Treatment with danicamtiv also improved left atrial (LA) volume and function, a new and potentially important finding given LA size is a well-established prognostic factor for atrial fibrillation. Data from nonclinical studies indicate that danicamtiv directly activates the LV and LA, providing mechanistic rationale for the robust changes observed clinically. These data were presented at the European Society of Cardiology’s Heart Failure Association (HFA) Discoveries online event, and published in the European Journal of Heart Failure. |
Pending circumstances related to the coronavirus pandemic, MyoKardia expects to initiate a Phase 2 study in patients with genetic dilated cardiomyopathy (DCM) in the second half of 2020 and a Phase 2 study in patients with systolic heart failure and paroxysmal or persistent atrial fibrillation in the first half of 2021.
Research
| • | Entered into Collaboration with Fulcrum Therapeutics: MyoKardia announced a strategic collaboration and license agreement with Fulcrum Therapeutics. Under the agreement, MyoKardia will access Fulcrum’s proprietary target discovery engine to identify therapeutics that control the expression of genes known to be underlying drivers of genetic cardiomyopathies. MyoKardia will be responsible for all development and commercialization activities for, and will have global rights to, any potential therapeutics identified through this collaboration. |
In March 2020, in response to the coronavirus pandemic, MyoKardia paused new patient enrollment in the MAVA-LTE long-term extension study of mavacamten and in the Phase 1 healthy volunteer study of MYK-224. The company has subsequently resumed enrollment in both studies.
Recent Corporate Highlights
| • | Announced New General Counsel: MyoKardia appointed Denelle J. Waynick as General Counsel and Corporate Secretary. Cynthia Ladd, MyoKardia’s former General Counsel, will be retiring following a transition period in the second half of 2020. |
| • | Completed Successful Follow-On Offering: MyoKardia completed a follow-on offering of 6,037,500 shares of its common stock at a public offering price of $105.00 per share, raising approximately $605.0 million in net proceeds. MyoKardia anticipates using net proceeds from the offering to support the regulatory approval process and potential commercial launch of mavacamten for the treatment of obstructive HCM; to fund ongoing and potential later-stage clinical trials of mavacamten in non-obstructive HCM and HFpEF, danicamtiv in targeted segments of systolic heart failure and MYK-224; to advance ACT-1 and LUS-1 into clinical development; to fund ongoing preclinical, discovery and research programs, and for working capital, business development and other general corporate purposes. |
Second Quarter 2020 Financial Results
Cash Position: Cash, cash equivalents and investments as of June 30, 2020 were $918.1 million, compared to $430.3 million as of December 31, 2019. The increase in MyoKardia’s cash position is primarily attributable to net proceeds of approximately $605.0 million from MyoKardia’s follow-on offering of common stock, which priced in May 2020.
R&D Expenses: Research and development expenses were $44.3 million for the second quarter of 2020, compared to $27.7 million for the same period in 2019. The increase in R&D expenses for the
second quarter of 2020 was primarily driven by the absence of R&D reimbursements from Sanofi, our previous collaboration partner, increased personnel costs including stock-based compensation, as well as increases in R&D infrastructure, consulting, and contract manufacturing expenses.
G&A Expenses: General and administrative expenses were $20.3 million for the three months ended June 30, 2020, compared to $13.9 million for the same period in 2019. The increase in G&A expenses for the second quarter of 2020 was primarily driven by an increase in personnel costs including stock-based compensation, as well as increases in professional fees and marketing expenses.
Net Loss: Net loss for the second quarter of 2020 was $63.6 million ($1.27 per share), compared to a net loss of $38.2 million ($0.83 loss per share) for the second quarter of 2019.
Conference Call and Webcast
MyoKardia management will host a conference call and live audio webcast on Tuesday, August 4, 2020, at 4:30 p.m. ET / 1:30 p.m. PT to discuss current operations and second quarter 2020 financial results. The call may be accessed by phone by calling 844-494-0193 from the U.S. and Canada or 508-637-5584 internationally and using the conference ID 4340819. The webcast may be accessed live on the Investor Relations section of the company's website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 90 days following the call.
About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the biomechanical underpinnings of disease; 2) targeting the proteins that modulate a given condition; 3) identifying patient populations with shared disease characteristics; and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224.
MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.
Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding timing with respect to submission of a New Drug Application to the FDA for mavacamten, expectation and timing of approval and launch of mavacamten in the US, the likelihood of developing evidence supporting mavacamten’s use as a backbone therapy for individuals with HCM and other populations, the ongoing enrollment of patients in the Phase 3 VALOR-HCM clinical trial as well as our expectation that the clinical trial design will result in direct clinical evidence supporting mavacamten’s ability to improve outcomes for individuals with HCM by reducing the need for invasive SRT procedures, the clinical and therapeutic potential of danicamtiv, the ability to continue to discover and develop our pipeline of targeted cardiovascular medicines, as well as the potential for identifying therapeutics controlling the expression of genes known to be underlying drivers of genetic cardiomyopathies and the subsequent potential development and commercialization as a result of the collaboration with Fulcrum Therapeutics, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and
on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements ad will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the development and regulation of our product candidates, as well as those set forth in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and our other filings with the SEC. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Michelle Corral
Executive Director, Corporate Communications and Investor Relations
MyoKardia, Inc.
650-351-4690
ir@myokardia.com
Hannah Deresiewicz (Investors)
Stern Investor Relations, Inc.
212-362-1200
hannah.dereseiwicz@sternir.com
Julie Normart (Media)
W2O
628-213-3754
jnormart@w2ogroup.com
MYOKARDIA, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
(Unaudited)
| | June 30, 2020 | | | December 31, 2019 | |
Assets | | | | | | | | |
Current assets | | | | | | | | |
Cash and cash equivalents | | $ | 659,107 | | | $ | 101,436 | |
Short-term investments | | | 258,946 | | | | 314,691 | |
Prepaid expenses and other current assets | | | 7,075 | | | | 7,709 | |
Total current assets | | | 925,128 | | | | 423,836 | |
Property and equipment, net | | | 19,703 | | | | 15,743 | |
Operating lease right-of-use assets | | | 51,189 | | | | 417 | |
Long-term investments | | | — | | | | 14,153 | |
Restricted cash and other | | | 2,706 | | | | 1,945 | |
Total assets | | $ | 998,726 | | | $ | 456,094 | |
Liabilities and stockholders’ equity | | | | | | | | |
Current liabilities | | | | | | | | |
Accounts payable | | $ | 3,349 | | | $ | 6,237 | |
Accrued liabilities | | | 32,600 | | | | 41,292 | |
Operating lease liabilities - current | | | 8,042 | | | | 383 | |
Total current liabilities | | | 43,991 | | | | 47,912 | |
Operating lease liability | | | 44,188 | | | | — | |
Other long-term liabilities | | | 1,908 | | | | 1,908 | |
Total liabilities | | | 90,087 | | | | 49,820 | |
Commitments and contingencies | | | | | | | | |
Stockholders’ equity | | | | | | | | |
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding | | | — | | | | — | |
Common stock, $0.0001 par value, 150,000,000 shares authorized at June 30, 2020 and December 31, 2019; 52,965,033 and 46,379,073 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively | | | 5 | | | | 5 | |
Additional paid-in capital | | | 1,520,101 | | | | 884,486 | |
Accumulated other comprehensive income | | | 752 | | | | 549 | |
Accumulated deficit | | | (612,219 | ) | | | (478,766 | ) |
Total stockholders’ equity | | | 908,639 | | | | 406,274 | |
Total liabilities and stockholders’ equity | | $ | 998,726 | | | $ | 456,094 | |
| | | | | | | | |
MYOKARDIA, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)
| | Three Months Ended June 30, | | | Six Months Ended June 30, | |
| | 2020 | | | 2019 | | | 2020 | | | 2019 | |
Operating expenses: | | | | | | | | | | | | | | | | |
Research and development | | $ | 44,334 | | | $ | 27,708 | | | $ | 96,212 | | | $ | 53,898 | |
Selling, general and administrative | | | 20,251 | | | | 13,856 | | | | 40,153 | | | | 27,407 | |
Total operating expenses | | | 64,585 | | | | 41,564 | | | | 136,365 | | | | 81,305 | |
Loss from operations | | | (64,585 | ) | | | (41,564 | ) | | | (136,365 | ) | | | (81,305 | ) |
Interest and other income, net | | | 1,012 | | | | 3,172 | | | | 2,924 | | | | 5,443 | |
Loss before income taxes | | | (63,573 | ) | | | (38,392 | ) | | | (133,441 | ) | | | (75,862 | ) |
Income tax expense (benefit) | | | 12 | | | | (218 | ) | | | 12 | | | | (218 | ) |
Net loss | | | (63,585 | ) | | | (38,174 | ) | | | (133,453 | ) | | | (75,644 | ) |
Other comprehensive income | | | 81 | | | | 201 | | | | 203 | | | | 564 | |
Comprehensive loss | | $ | (63,504 | ) | | $ | (37,973 | ) | | $ | (133,250 | ) | | $ | (75,080 | ) |
Net loss per share, basic and diluted | | $ | (1.27 | ) | | $ | (0.83 | ) | | $ | (2.77 | ) | | $ | (1.75 | ) |
Weighted average number of shares used to compute net loss per share, basic and diluted | | | 49,878,578 | | | | 46,065,901 | | | | 48,222,787 | | | | 43,301,417 | |
